RxDoctor Payments Data

Shawn Todd, DO

Urology · Lufkin, TXNPI 1982916227

Payments from drug & device makers

$4,214in general payments, 2019–2025

Across 173 payments — averaging $24.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$1K
  • Teleflex LLC$437
  • Sumitomo Pharma America, Inc.$385
  • Neotract Inc.$351
  • Endo Pharmaceuticals Inc.$294
  • Procept Biorobotics Corporation$270
  • plus $1K from 22 others

What the payments were for

  • Speaking & faculty fees$47311%
  • Food & beverage$3,71888%
  • Education$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,214 in reported general payments places this provider in the 50th percentile of 878 urology providers in Texas.

See all urology providers in Texas

Medicare billing

Part B allowed, 2024
$416,884
Medicare patients
935
Services billed
6,009

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron353$241,474
MyrbetriqMirabegron323$193,599
LinzessLinaclotide29$16,821
Methenamine Hippurate168$13,349
Testosterone Cypionate207$9,285
Tamsulosin Hcl816$8,999
Oxybutynin Chloride ErOxybutynin Chloride498$6,639
Finasteride462$5,893
Trimethoprim119$5,421
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst182$4,004
Silodosin34$3,097
Potassium Citrate ErPotassium Citrate31$2,403
Ciprofloxacin Hcl591$2,303
Fesoterodine Fumarate ErFesoterodine Fumarate17$2,285
Testosterone11$1,361

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$385$241,474353 claims
Astellas Pharma US IncMyrbetriq$133$193,599323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 878 urology providers in Texas.

Other urology in Lufkin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →